Results 31 to 40 of about 48,845 (222)

Osteonecrosis of the jaws produced by sunitinib : a systematic review [PDF]

open access: yes, 2019
Tyrosine kinase receptor family is involved in tumor growth, pathological angiogenesis and the progression (metastasis) of cancer. Sunitinib (Sutent®) inhibits members of the tyrosine kinase receptor family affecting the induction of angiogenesis and ...
Ramírez, L.   +15 more
core   +1 more source

Long Non-coding RNA CCAT1 Acts as an Oncogene and Promotes Sunitinib Resistance in Renal Cell Carcinoma

open access: yesFrontiers in Oncology, 2020
Although sunitinib contributes to prolonging the progression-free survival of metastatic renal cell carcinoma significantly, the universal presence of resistance limits the initial response rate and restricts durable responses. The mechanisms involved in
Liping Shan, Wei Liu, Yunhong Zhan
doaj   +1 more source

Autophagy inhibition improves sunitinib efficacy in pancreatic neuroendocrine tumors via a lysosome-dependent mechanism. [PDF]

open access: yes, 2017
Increasing the efficacy of approved systemic treatments in metastasized pancreatic neuroendocrine tumors (PanNETs) is an unmet medical need. The anti-angiogenic tyrosine kinase inhibitor sunitinib is approved for PanNET treatment. Additionally, sunitinib
Normand, Lea Elena Haaning   +26 more
core   +2 more sources

Tumor flare of brain metastases upon dose interruption of sunitinib in a patient with metastatic renal cell carcinoma

open access: yesCancer Treatment and Research Communications, 2021
Brain metastases from renal cell carcinoma are associated with poor prognosis. Sunitinib is a multi-targeted tyrosine kinase inhibitor used for the treatment of metastatic renal cell carcinoma.
Mali Amirault   +6 more
doaj   +1 more source

Sunitinib-Induced Adrenal Crisis in a Patient with Pre-Existing Immunotherapy-Related Hypopituitarism

open access: yes, 2022
Sunitinib is a tyrosine kinase inhibitor that is frequently used in the treatment of metastatic renal cell carcinoma (mRCC). As a multikinase inhibitor, numerous off-target side effects of this medication are widely recognized.
David Song (13393110)   +3 more
core  

Sunitinib treatments.

open access: yes, 2014
Representative pictures of the effect of sunitinib treatments on the HepG2 (with giant lysosomes) and SNU475 cell lines (with normal lysosomes). The rows show the treatment conditions: 1) Sunitinib 12 µM alone for 12 hours; 2) One hour of pre-incubation ...
Paola Cetrangolo (672519)   +9 more
core   +1 more source

Sunitinib-induced asthenia: from molecular basis to clinical relief [PDF]

open access: yes, 2011
[Abstract] Asthenia-fatigue syndrome (AFS) is defined as a persistent, subjective sense of tiredness related to cancer or its treatment and greatly impacts quality of life among cancer patients.
Aparicio Gallego, Guadalupe   +6 more
core   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

open access: yesMolecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David   +12 more
wiley   +1 more source

Fractioned Dose Regimen of Sunitinib for Patients with Gastrointestinal Stromal Tumor: A Pharmacokinetic and Treatment Efficacy Study

open access: yesTranslational Oncology, 2014
AIM: Sunitinib has shown benefit in patients with imatinib (IM)–resistant gastrointestinal stromal tumor (GIST). However, its advantages are somewhat diminished because of associated toxicities.
Yen-Yang Chen   +8 more
doaj   +1 more source

Establishment of a Multi‐Stage In Vitro Screening Platform to Identify Candidate Compounds for Intestinal Mucosal Damage in Inflammatory Bowel Disease

open access: yesAdvanced Healthcare Materials, EarlyView.
A multi‐stage screening platform integrating human intestinal organoids with an intestinal microphysiological system enables evaluation of both inflammatory responses and mucosal architecture in inflammatory bowel disease. The platform distinguishes compounds that suppress inflammation from those that also preserve mucosal architecture, providing a ...
Fuki Yokoi   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy